177 related articles for article (PubMed ID: 33804655)
1. Efficacy of Targeted Radionuclide Therapy Using [
Akil H; Quintana M; Raymond JH; Billoux T; Benboubker V; Besse S; Auzeloux P; Delmas V; Petit V; Larue L; D'Incan M; Degoul F; Rouanet J
Cancers (Basel); 2021 Mar; 13(6):. PubMed ID: 33804655
[TBL] [Abstract][Full Text] [Related]
2. Phase I study of [
Thivat E; Rouanet J; Auzeloux P; Sas N; Jouberton E; Levesque S; Billoux T; Mansard S; Molnar I; Chanchou M; Fois G; Maigne L; Chezal JM; Miot-Noirault E; D'Incan M; Durando X; Cachin F
BMC Cancer; 2022 Apr; 22(1):417. PubMed ID: 35428211
[TBL] [Abstract][Full Text] [Related]
3. Targeted Radionuclide Therapy Decreases Melanoma Lung Invasion by Modifying Epithelial-Mesenchymal Transition-Like Mechanisms.
Akil H; Rouanet J; Viallard C; Besse S; Auzeloux P; Chezal JM; Miot-Noirault E; Quintana M; Degoul F
Transl Oncol; 2019 Nov; 12(11):1442-1452. PubMed ID: 31421458
[TBL] [Abstract][Full Text] [Related]
4. Exploring the In Vitro and In Vivo Therapeutic Potential of BRAF and MEK Inhibitor Combination in NRAS-Mutated Melanoma.
Niessner H; Hüsch A; Kosnopfel C; Meinhardt M; Westphal D; Meier F; Schilling B; Sinnberg T
Cancers (Basel); 2023 Nov; 15(23):. PubMed ID: 38067230
[TBL] [Abstract][Full Text] [Related]
5. [¹²³I]ICF01012 melanoma imaging and [¹³¹I]ICF01012 dosimetry allow adapted internal targeted radiotherapy in preclinical melanoma models.
Viallard C; Perrot Y; Boudhraa Z; Jouberton E; Miot-Noirault E; Bonnet M; Besse S; Mishellany F; Cayre A; Maigne L; Rbah-Vidal L; D'Incan M; Cachin F; Chezal JM; Degoul F
Eur J Dermatol; 2015; 25(1):29-35. PubMed ID: 25548082
[TBL] [Abstract][Full Text] [Related]
6. BRAF Inhibitors Amplify the Proapoptotic Activity of MEK Inhibitors by Inducing ER Stress in NRAS-Mutant Melanoma.
Niessner H; Sinnberg T; Kosnopfel C; Smalley KSM; Beck D; Praetorius C; Mai M; Beissert S; Kulms D; Schaller M; Garbe C; Flaherty KT; Westphal D; Wanke I; Meier F
Clin Cancer Res; 2017 Oct; 23(20):6203-6214. PubMed ID: 28724666
[No Abstract] [Full Text] [Related]
7. Immune checkpoint inhibitors reverse tolerogenic mechanisms induced by melanoma targeted radionuclide therapy.
Rouanet J; Benboubker V; Akil H; Hennino A; Auzeloux P; Besse S; Pereira B; Delorme S; Mansard S; D'Incan M; Degoul F; Rouzaire PO
Cancer Immunol Immunother; 2020 Oct; 69(10):2075-2088. PubMed ID: 32447411
[TBL] [Abstract][Full Text] [Related]
8. The clinical significance of BRAF and NRAS mutations in a clinic-based metastatic melanoma cohort.
Ekedahl H; Cirenajwis H; Harbst K; Carneiro A; Nielsen K; Olsson H; Lundgren L; Ingvar C; Jönsson G
Br J Dermatol; 2013 Nov; 169(5):1049-55. PubMed ID: 23855428
[TBL] [Abstract][Full Text] [Related]
9. C57BL/6 congenic mouse NRAS
Petit V; Raymond J; Alberti C; Pouteaux M; Gallagher SJ; Nguyen MQ; Aplin AE; Delmas V; Larue L
Pigment Cell Melanoma Res; 2019 Nov; 32(6):829-841. PubMed ID: 31251472
[TBL] [Abstract][Full Text] [Related]
10. Targeting DNA repair by coDbait enhances melanoma targeted radionuclide therapy.
Viallard C; Chezal JM; Mishellany F; Ranchon-Cole I; Pereira B; Herbette A; Besse S; Boudhraa Z; Jacquemot N; Cayre A; Miot-Noirault E; Sun JS; Dutreix M; Degoul F
Oncotarget; 2016 Mar; 7(11):12927-36. PubMed ID: 26887045
[TBL] [Abstract][Full Text] [Related]
11. Radiation dosimetry of [
Jouberton E; Perrot Y; Dirat B; Billoux T; Auzeloux P; Cachin F; Chezal JM; Filaire M; Labarre P; Miot-Noirault E; Millardet C; Valla C; Vidal A; Degoul F; Maigne L
Med Phys; 2018 Nov; 45(11):5251-5262. PubMed ID: 30179267
[TBL] [Abstract][Full Text] [Related]
12. Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations.
Greger JG; Eastman SD; Zhang V; Bleam MR; Hughes AM; Smitheman KN; Dickerson SH; Laquerre SG; Liu L; Gilmer TM
Mol Cancer Ther; 2012 Apr; 11(4):909-20. PubMed ID: 22389471
[TBL] [Abstract][Full Text] [Related]
13. Theranostic Approach for Metastatic Pigmented Melanoma Using ICF15002, a Multimodal Radiotracer for Both PET Imaging and Targeted Radionuclide Therapy.
Rbah-Vidal L; Vidal A; Billaud EM; Besse S; Ranchon-Cole I; Mishellany F; Perrot Y; Maigne L; Moins N; Guerquin-Kern JL; Degoul F; Chezal JM; Auzeloux P; Miot-Noirault E
Neoplasia; 2017 Jan; 19(1):17-27. PubMed ID: 27987437
[TBL] [Abstract][Full Text] [Related]
14. P53 and MITF/Bcl-2 identified as key pathways in the acquired resistance of NRAS-mutant melanoma to MEK inhibition.
Najem A; Krayem M; Salès F; Hussein N; Badran B; Robert C; Awada A; Journe F; Ghanem GE
Eur J Cancer; 2017 Sep; 83():154-165. PubMed ID: 28738256
[TBL] [Abstract][Full Text] [Related]
15. Efficient Suppression of NRAS-Driven Melanoma by Co-Inhibition of ERK1/2 and ERK5 MAPK Pathways.
Adam C; Fusi L; Weiss N; Goller SG; Meder K; Frings VG; Kneitz H; Goebeler M; Houben R; Schrama D; Schmidt M
J Invest Dermatol; 2020 Dec; 140(12):2455-2465.e10. PubMed ID: 32376279
[TBL] [Abstract][Full Text] [Related]
16. ROS production induced by BRAF inhibitor treatment rewires metabolic processes affecting cell growth of melanoma cells.
Cesi G; Walbrecq G; Zimmer A; Kreis S; Haan C
Mol Cancer; 2017 Jun; 16(1):102. PubMed ID: 28595656
[TBL] [Abstract][Full Text] [Related]
17. ER Translocation of the MAPK Pathway Drives Therapy Resistance in BRAF-Mutant Melanoma.
Ojha R; Leli NM; Onorati A; Piao S; Verginadis II; Tameire F; Rebecca VW; Chude CI; Murugan S; Fennelly C; Noguera-Ortega E; Chu CT; Liu S; Xu X; Krepler C; Xiao M; Xu W; Wei Z; Frederick DT; Boland G; Mitchell TC; Karakousis GC; Schuchter LM; Flaherty KT; Zhang G; Herlyn M; Koumenis C; Amaravadi RK
Cancer Discov; 2019 Mar; 9(3):396-415. PubMed ID: 30563872
[TBL] [Abstract][Full Text] [Related]
18. [Characterization of genetic alterations in primary human melanomas carrying BRAF or NRAS mutation].
Lázár V
Magy Onkol; 2013 Jun; 57(2):96-9. PubMed ID: 23795354
[TBL] [Abstract][Full Text] [Related]
19. MEK/CDK4,6 co-targeting is effective in a subset of NRAS, BRAF and 'wild type' melanomas.
Posch C; Sanlorenzo M; Ma J; Kim ST; Zekhtser M; Ortiz-Urda S
Oncotarget; 2018 Oct; 9(79):34990-34995. PubMed ID: 30405888
[TBL] [Abstract][Full Text] [Related]
20. Magnolol induces cell death through PI3K/Akt-mediated epigenetic modifications boosting treatment of BRAF- and NRAS-mutant melanoma.
Emran AA; Chinna Chowdary BR; Ahmed F; Hammerlindl H; Huefner A; Haass NK; Schuehly W; Schaider H
Cancer Med; 2019 Mar; 8(3):1186-1196. PubMed ID: 30793515
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
